Protein Helps Neurons Maintain Dopamine Production in Models of Parkinson's Disease
|
By LabMedica International staff writers Posted on 20 Oct 2016 |

Image: Diagram shows how the neuropeptide Prokineticin-2 (PK2) is rapidly induced during early stages of neurotoxic stress and secreted into extracellular spaces. PK2 is thought to act as a protective mechanism that helps neurons cope with Parkinson’s disease (Photo courtesy of Dr. Anumantha Kanthasamy, Iowa State University).
A team of neurodegenerative disease researchers has identified a protein that seems to help neurons in the brain maintain dopamine production.
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.
They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).
Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.
PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.
“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”
Related Links:
Iowa State University
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








